By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Nektar Therapeutics (CA) 

Corporate Headquarters
455 Mission Bay Boulevard South
San Francisco  California  94158  U.S.A.
Phone: 415-482-5300, Toll Free 855-482-NKTR (6587) Fax: 415-339-5300


SEARCH JOBS

Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar has a robust R&D pipeline of potentially high-value therapeutics in oncology, pain and other therapeutic areas. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for MOVANTIK™(naloxegol), the first FDA-approved once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of opioid-induced constipation (OIC), in adult patients with chronic, non-cancer pain. The AstraZeneca agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of MOVANTIK and an opioid. NKTR-181, a wholly-owned mu-opioid analgesic molecule for chronic pain conditions, has completed Phase 2 development. NKTR-171, a wholly-owned new sodium channel blocker being developed as an oral therapy for the treatment of peripheral neuropathic pain, is in Phase 1 clinical development. In oncology, etirinotecan pegol (NKTR-102) is being evaluated in a Phase 3 clinical study (the BEACON study) for the treatment of metastatic breast cancer. In hemophilia, BAX 855, a longer-acting PEGylated Factor VIII therapeutic is in Phase 3 development conducted by partner Baxter. In anti-infectives, Amikacin Inhale is in Phase 3 studies conducted by Bayer Healthcare as an adjunctive treatment for intubated and mechanically ventilated patients with Gram-negative pneumonia.

Nektar's technology has enabled nine approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including AstraZeneca's MOVANTIK, UCB's Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia.

The company was founded in 1990 and is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India.




Key Statistics


Email: nektar@nektar.com
Ownership: Public

Web Site: Nektar Therapeutics (CA)
Employees: 429
Symbol: NKTR
 









Company News
Nektar Therapeutics (CA) (NKTR) Presents Preclinical Study Findings For Etirinotecan Pegol (NKTR-102) In Combination With A PARP Inhibitor In BRCA1-Deficient Cancer Model 11/20/2014 10:09:11 AM
Nektar Therapeutics (CA) (NKTR) Reports Financial Results For The Third Quarter Of 2014 11/7/2014 8:06:42 AM
Nektar Therapeutics (CA) (NKTR) To Announce Financial Results For The Third Quarter 2014 On Thursday, November 6, 2014, After Close Of U.S.-Based Financial Markets 10/30/2014 9:39:02 AM
Nektar Therapeutics (CA) (NKTR) Announces MOVENTIG® (naloxegol) Receives Positive CHMP Opinion In EU For Treatment Of Adults With Opioid-Induced Constipation 9/26/2014 8:36:48 AM
Nektar Therapeutics (CA) (NKTR) Presents Positive Preclinical Data On Oral, Peripherally-Acting Kappa Agonist Molecules At 2014 American Academy Of Pain Management Meeting 9/19/2014 8:10:52 AM
FDA Approves AstraZeneca PLC (AZN), Nektar Therapeutics (CA) (NKTR)'s MOVANTIK™ For Opioid-Induced Constipation 9/16/2014 12:45:25 PM
Nektar Therapeutics (CA) (NKTR) Reports Financial Results For The Second Quarter Of 2014 8/1/2014 7:00:01 AM
Nektar Therapeutics (CA) (NKTR) To Announce Financial Results For The Second Quarter 2014 On Thursday, July 31, 2014, After Close Of U.S.-Based Financial Markets 7/23/2014 12:17:04 PM
Nektar Therapeutics (CA) (NKTR) Stock Trading Halted Today; FDA Advisory Committee To Discuss Peripherally-Acting Opioid Receptor Antagonists 6/11/2014 9:42:15 AM
Nektar Therapeutics (CA) (NKTR) Presents Positive Preclinical Data For NKTR-214, A Novel Cancer Immunotherapy, At 50th American Society of Clinical Oncology Meeting 6/2/2014 6:46:36 AM
12345678910...
//-->